scholarly journals Quadruple‐hit pleomorphic mantle cell lymphoma with MYC , BCL2 , BCL6 , and CCND1 gene rearrangements

Author(s):  
Wei Liu ◽  
Xiaoqian Chen ◽  
Jianlin Fan ◽  
Mingqing Zhu ◽  
Hongjie Shen ◽  
...  
Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3752-3752 ◽  
Author(s):  
Harvey A Greisman ◽  
Timothy C. Greiner ◽  
Hye Son Yi ◽  
Noah G. Hoffman

Abstract Mantle cell lymphoma (MCL) is characterized by the over-expression of cyclin D1 (CCND1) as a result of the chromosomal fusion of the CCND1 gene at 11q13 to the immunoglobulin heavy chain (IgH) locus at 14q32. Up to 50% of t(11;14) breakpoints in MCL map to the ~200bp major translocation cluster (MTC) near the CCND1 gene. MCL patients having MTC breakpoints can be easily monitored for minimal residual disease (MRD) using a sensitive genomic PCR assay that employs consensus IgH joining (JH) and CCND1-MTC primers. The majority of MCL patients, however, have t(11;14) breakpoints that are scattered across a ~380kb region outside the MTC and that have therefore been difficult to clone and use for MRD monitoring. We recently described Translocation-CGH (TGH), a modification of array-CGH that utilizes tiling-density arrays to map the genomic breakpoints of balanced translocations (including IgH fusions to BCL2, MYC and CCND1 loci) to ~100bp resolution and simultaneously detects genomic imbalances. We now report the use of TGH on a series of 33 confirmed MCL cases with CCND1 translocations, including 10 with MTC breakpoints and 23 with non-MTC breakpoints. In 32 of 33 cases (97%), we demonstrate the fusion of CCND1 to a JH segment. The remaining case shows a genomic gain that encompasses the CCND1 gene and whose centromeric end extends to the MTC, presumably reflecting duplication of a derivative chromosome that contains a CCND1 fusion at the MTC to an as yet unidentified partner locus. Sequence analysis of the 23 non-MTC breakpoints reveals distribution across a ~330kb genomic region that surrounds the MTC and extends to within 3kb of the CCND1 transcription start site. Nine (39%) of the 23 non-MTC breakpoints were localized to simple or interspersed DNA repeats, including six (26%) in LINE1 elements, which comprise 11.7% of the CCND1 breakpoint region, and one each in LTR-ERVL, DNA-AcHOBO and simple-(GGAA)n repeat elements. No breakpoints were identified within SINE/Alu repeats, which comprise 11.0% of the breakpoint region. The mechanism underlying the possible preference for LINE1 elements in CCND1 translocations (p=0.045, exact binomial calculation) is unknown and additional studies will be required to elucidate it. Preliminary sequence analysis of the der(14)-derived JH-CCND1 junctions and the reciprocal der(11) breakpoints shows features similar to those described previously for MTC breakpoints. Interestingly, two of the non-MTC breakpoints are 1bp and ~170bp from previously identified breakpoints in the MCL cell lines MO1094 and Granta 519, respectively. However, we found no convincing evidence for ‘minor’ translocation clusters like those identified at the BCL2 locus in a subset of t(14;18)-positive lymphomas. In summary, the current study establishes the usefulness of TGH for identifying widely-scattered non-MTC breakpoints, which will enable the design of highly-sensitive and patient-specific genomic PCR assays for MRD monitoring in the vast majority of MCL patients.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 398-398
Author(s):  
Harvey A Greisman ◽  
Zhengfei Lu ◽  
Albert G Tsai ◽  
Timothy C. Greiner ◽  
Hye Son Yi ◽  
...  

Abstract Abstract 398 Most t(11;14)(q13;q32) breakpoints in mantle cell lymphoma (MCL) are scattered across a large genomic region centromeric to the CCND1 gene on chromosome 11q13. However, few t(11;14) breakpoints outside the major translocation cluster (MTC) have been sequenced. We report our analysis of 56 IGH-CCND1 fusion sequences from 32 non-MTC cases of MCL. Our analysis reveals remarkable breakpoint diversity at both CCND1 and IGH loci. The CCND1 breakpoints are located from 2 kb to 331 kb from the CCND1 gene, including 12 breakpoints (38%) in the 220kb region centromeric to the MTC, which is itself located 110 kb centromeric to the CCND1 gene. Twenty-one cases had a JH coding end breakpoint on the der(14) chromosome and a DH coding end breakpoint on the der(11). Two cases had der(14) and der(11) breakpoints derived from the coding and signal ends of the same JH or DH gene segment; one case had a JH/DH breakpoint on the der(14) and a VH breakpoint on the der(11); and one case had a breakpoint in the JH region located >100 bases from the nearest RSS motif, suggesting a RAG-independent break at IGH. No der(11) breakpoint could be amplified in eight cases. In sixteen cases (50%), one or both CCND1 breakpoints were within 4 bases of a CpG dinucleotide, a feature characteristic of translocation breakpoints in many human B cell lymphomas. Three CpG-associated “microclusters” were identified, i.e. breakpoints in two different tumors located at or near the same CpG site. Breakpoints in the sixteen (50%) “non-CpG” cases showed a significant association with AID hotspot motifs at the CCND1 locus. In addition, the non-CpG breakpoints were more likely to: 1) be located telomeric to the MTC, 2) involve 3' JH and 5' DH gene segments, and 3) be associated with immunoglobulin lambda light chain restriction; features that suggest occurrence at a late stage of pre-B cell maturation. In contrast, the CpG-associated breakpoints were: 1) more likely to be centromeric to the MTC, 2) not biased in their JH or DH segment usage, and 3) associated with kappa light chain restriction; features suggesting occurrence in an earlier pre-B cell or pro-B cell. Our results implicate AID in chromosomal breakage at both CpG and non-CpG sites within the CCND1 locus and suggest that AID and RAG collude to generate the chromosomal breaks underlying the t(11;14). Our findings also suggest that IGH-CCND1 rearrangements can occur at different stages of pre-B cell maturation. This study provides novel insights into the mechanism and developmental timing of the t(11;14) in human MCL, features that are likely to be relevant to a broad range of human lymphomas. Disclosures: Greisman: Signature Genomics, LLC: Patents & Royalties. Yi:Signature Genomics, LLC: Patents & Royalties.


2019 ◽  
Author(s):  
Charles Tong ◽  
Peter Papagiannopoulos ◽  
Michael Feldman ◽  
Nithin Adappa ◽  
James Palmer

2006 ◽  
Vol preprint (2007) ◽  
pp. 1
Author(s):  
Kristi Smock ◽  
Hassan Yaish ◽  
Mitchell Cairo ◽  
Mark Lones ◽  
Carlynn Willmore-Payne ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document